The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $35.11, a high ...

The pumps themselves generate just over half ... Revenue Growth: Over the 3M period, Tandem Diabetes Care showcased positive performance, achieving a revenue growth rate of 43.62% as of 31 ...

slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com.

slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com.

CMO Jordan Pinsker said Tandem hopes to expand Medicare coverage of its automated insulin delivery systems with results of a ...

With equity markets reeling due to President Donald Trump's tariffs, many investors are taking this opportunity to buy shares ...

Tandem Diabetes Care, Inc. TNDM shares soared 7.6% in the last trading session to close at $17.61. The move was backed by solid volume with far more shares changing hands than in a normal session.

Tandem Diabetes (TNDM) announced the United States commercial launch of Control-IQ+ technology, the latest generation of the company’s advanced ...

Mizuho initiated coverage of Tandem Diabetes (TNDM) with a Neutral rating and $20 price target The firm’s neutral stance reflects both the ...

In this episode of Vanguards of Health Care, Sheridan sits down with BI analyst Matt Henriksson for an in-depth interview about Tandem’s Mobi pump, designed for discretion and simplicity, and the ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq ... Control-IQ+, compatible with both the t:slim X2 insulin pump and Tandem Mobi System, is now available for people with type ...

Tandem Diabetes Care, Inc. TNDM shares soared 7.6% in the ... the company’s reported sales grew by a staggering 44%, while worldwide pump shipments increased by more than 25%.